1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). (September 2015) - Miles, D.; Puglisi, F.; Schneeweiss, A.; Ciruelos, E.; Peretz-Yablonski, T.; Moreno, K.; Restuccia, E.; Lasserre, S.; Bachelot, T.